Table 2.
Characteristics of the eligible studies evaluating the psoriasis severity (assessed by PASI score) in psoriatic patients with and without NAFLD
| References (PMID) | Country | Patients, n | Age, yearsb | PASIb | Diagnosis of NAFLD | Prevalence of NAFLD, n (%) | Risk of NAFLD in PsA vs. PsO (OR 95% CI) | Mean PASI difference in patients with NAFLD (IV, 95% CI)a |
|---|---|---|---|---|---|---|---|---|
| Gisondi et al. [21] (19560226) | Italy | 130 | 51.2 ± 13.4 | 13.1 ± 11.0 | US | 61 (47) | 1.02 (0.51–2.03) | 7.90 (4.67–11.13) |
| Miele et al. [31] (19664838) | Italy | 84 | 50.1 ± 15 | 16.4 ± 10.0 | US, biopsy (5 cases) | 84 (59.2) | 3.53 (0.98–12.77) | 2.00 (− 1.96 to 5.96) |
| Madanagobalane and Anandan [23] (22672067) | India | 333 | 46.3 ± 11.5 | 6.5 ± 10.8 | US and TE | 58 (17.4) | 3.71 (1.89–7.30) | 2.20 (− 0.62 to 5.02) |
| Roberts et al. [33] (25521607) | United States | 103 | 52.7 ± 12 | 5.2 ± 4.9 | TE, biopsy (52 cases) | 48 (46.6) | NR | 2.21 (0.64–3.79) |
| Gisondi et al. [22] (26537011) | Italy | 124 | 55.0 ± 12.0 | 13.0 ± 10.0 | US | 55 (44) | 1.00 (0.52–1.95) | 8.40 (5.14–11.66) |
| Narayanasamy et al. [32] (28053681) | India | 250 | 44.7 ± 12.0 | 27.8 ± 13.5 | US and TE | 113 (45.2) | NR | 9.69 (6.29–13.09) |
| Awosika et al. [20] (29942422) | United States | 101 | 44.2 ± 13.6 | 4.8 ± 2.1 | US | 21 (21.2) | NR | 0.72 (−0.20 to 1.64) |
| Magdaleno Tapial et al. [30] (31731325) | Spain | 71 | 46.7 ± 14 | 14.4 ± 6.5 | US and TE | 37 (52.1) | 2.15 (0.64–7.21) | 1.30 (0.30–2.30) |
NR not reported, OR odds ratio, US ultrasonography, IV interval variable, TE transitional elastography, PASI Psoriasis Area Severity Index, PsA psoriatic arthritis
aMedian (IQR)
bMean ± standard deviation